ATXS
Price
$4.96
Change
+$0.18 (+3.77%)
Updated
Jun 3 closing price
Capitalization
279.91M
68 days until earnings call
CRNX
Price
$32.10
Change
+$0.22 (+0.69%)
Updated
Jun 3 closing price
Capitalization
3.01B
65 days until earnings call
Interact to see
Advertisement

ATXS vs CRNX

Header iconATXS vs CRNX Comparison
Open Charts ATXS vs CRNXBanner chart's image
Astria Therapeutics
Price$4.96
Change+$0.18 (+3.77%)
Volume$456.27K
Capitalization279.91M
Crinetics Pharmaceuticals
Price$32.10
Change+$0.22 (+0.69%)
Volume$679.69K
Capitalization3.01B
ATXS vs CRNX Comparison Chart
Loading...
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ATXS vs. CRNX commentary
Jun 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ATXS is a Buy and CRNX is a StrongBuy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 04, 2025
Stock price -- (ATXS: $4.96 vs. CRNX: $32.10)
Brand notoriety: ATXS and CRNX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ATXS: 86% vs. CRNX: 67%
Market capitalization -- ATXS: $279.91M vs. CRNX: $3.01B
ATXS [@Biotechnology] is valued at $279.91M. CRNX’s [@Biotechnology] market capitalization is $3.01B. The market cap for tickers in the [@Biotechnology] industry ranges from $321.16B to $0. The average market capitalization across the [@Biotechnology] industry is $2.25B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ATXS’s FA Score shows that 0 FA rating(s) are green whileCRNX’s FA Score has 0 green FA rating(s).

  • ATXS’s FA Score: 0 green, 5 red.
  • CRNX’s FA Score: 0 green, 5 red.
According to our system of comparison, ATXS is a better buy in the long-term than CRNX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ATXS’s TA Score shows that 5 TA indicator(s) are bullish while CRNX’s TA Score has 5 bullish TA indicator(s).

  • ATXS’s TA Score: 5 bullish, 3 bearish.
  • CRNX’s TA Score: 5 bullish, 3 bearish.
According to our system of comparison, both ATXS and CRNX are a good buy in the short-term.

Price Growth

ATXS (@Biotechnology) experienced а +21.27% price change this week, while CRNX (@Biotechnology) price change was +8.81% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +5.76%. For the same industry, the average monthly price growth was +2.77%, and the average quarterly price growth was +0.74%.

Reported Earning Dates

ATXS is expected to report earnings on Aug 11, 2025.

CRNX is expected to report earnings on Aug 08, 2025.

Industries' Descriptions

@Biotechnology (+5.76% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRNX($3.01B) has a higher market cap than ATXS($280M). CRNX YTD gains are higher at: -37.219 vs. ATXS (-44.519). ATXS has higher annual earnings (EBITDA): -111.56M vs. CRNX (-373.49M). CRNX has more cash in the bank: 1.27B vs. ATXS (328M). ATXS has less debt than CRNX: ATXS (5.35M) vs CRNX (50.8M). CRNX has higher revenues than ATXS: CRNX (760K) vs ATXS (0).
ATXSCRNXATXS / CRNX
Capitalization280M3.01B9%
EBITDA-111.56M-373.49M30%
Gain YTD-44.519-37.219120%
P/E RatioN/AN/A-
Revenue0760K-
Total Cash328M1.27B26%
Total Debt5.35M50.8M11%
FUNDAMENTALS RATINGS
ATXS vs CRNX: Fundamental Ratings
ATXS
CRNX
OUTLOOK RATING
1..100
199
VALUATION
overvalued / fair valued / undervalued
1..100
58
Fair valued
92
Overvalued
PROFIT vs RISK RATING
1..100
10065
SMR RATING
1..100
9451
PRICE GROWTH RATING
1..100
9083
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ATXS's Valuation (58) in the Biotechnology industry is somewhat better than the same rating for CRNX (92) in the Pharmaceuticals Major industry. This means that ATXS’s stock grew somewhat faster than CRNX’s over the last 12 months.

CRNX's Profit vs Risk Rating (65) in the Pharmaceuticals Major industry is somewhat better than the same rating for ATXS (100) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than ATXS’s over the last 12 months.

CRNX's SMR Rating (51) in the Pharmaceuticals Major industry is somewhat better than the same rating for ATXS (94) in the Biotechnology industry. This means that CRNX’s stock grew somewhat faster than ATXS’s over the last 12 months.

CRNX's Price Growth Rating (83) in the Pharmaceuticals Major industry is in the same range as ATXS (90) in the Biotechnology industry. This means that CRNX’s stock grew similarly to ATXS’s over the last 12 months.

CRNX's P/E Growth Rating (100) in the Pharmaceuticals Major industry is in the same range as ATXS (100) in the Biotechnology industry. This means that CRNX’s stock grew similarly to ATXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ATXSCRNX
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
85%
Momentum
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
80%
MACD
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 1 day ago
80%
Bullish Trend 1 day ago
76%
Declines
ODDS (%)
Bearish Trend 27 days ago
90%
Bearish Trend 9 days ago
79%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
73%
N/A
Aroon
ODDS (%)
Bullish Trend 1 day ago
86%
Bearish Trend 1 day ago
69%
View a ticker or compare two or three
Interact to see
Advertisement
ATXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
CRNX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ITHSX52.10N/A
N/A
Hartford Capital Appreciation R4
KSOCX154.90N/A
N/A
Kinetics Small Cap Opportunities Adv C
LMCMX8.32N/A
N/A
Miller Income IS
PSMKX52.32N/A
N/A
Victory Pioneer Select Mid Cap Growth R6
GEMWX12.56N/A
N/A
Goldman Sachs Emerging Mkt Eq ex. Chn R6

ATXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ATXS has been loosely correlated with TRDA. These tickers have moved in lockstep 53% of the time. This A.I.-generated data suggests there is some statistical probability that if ATXS jumps, then TRDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ATXS
1D Price
Change %
ATXS100%
+3.77%
TRDA - ATXS
53%
Loosely correlated
+1.23%
KYMR - ATXS
53%
Loosely correlated
+1.04%
CRNX - ATXS
53%
Loosely correlated
+0.69%
XENE - ATXS
51%
Loosely correlated
+2.16%
DNLI - ATXS
51%
Loosely correlated
-0.21%
More

CRNX and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRNX has been loosely correlated with XNCR. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if CRNX jumps, then XNCR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRNX
1D Price
Change %
CRNX100%
+0.69%
XNCR - CRNX
58%
Loosely correlated
+6.53%
IDYA - CRNX
56%
Loosely correlated
+1.98%
DYN - CRNX
56%
Loosely correlated
+4.49%
TRDA - CRNX
55%
Loosely correlated
+1.23%
RVMD - CRNX
55%
Loosely correlated
-0.17%
More